The CDC has released the findings of a recent PROTECT study, assessing the efficacy of two doses of Pfizer-BioNTech vaccine in preventing infection from the Omicron variant amongst children 5 to 11 and adolescents 12 to 15 years of age. The study included clinical data from a cohort of 1,364 participants gathered from July 2021 to February 2022.

The report provides evidence that two doses of the Pfizer-BioNTech vaccine is effective in preventing both asymptomatic and symptomatic SARS-CoV-2 infection in this cohort.

Click on the link below to read the full report:

Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort